- Home
- SERV vs EDIT Comparison
SERV vs EDIT Comparison
Compare SERV & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SERV
- EDIT
- Stock Information
- Founded
- SERV 2017
- EDIT 2013
- Country
- SERV United States
- EDIT United States
- Employees
- SERV N/A
- EDIT N/A
- Industry
- SERV Industrial Specialties
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SERV Consumer Discretionary
- EDIT Health Care
- Exchange
- SERV Nasdaq
- EDIT Nasdaq
- Market Cap
- SERV 338.7M
- EDIT 327.0M
- IPO Year
- SERV N/A
- EDIT 2016
- Fundamental
- Price
- SERV $8.00
- EDIT $2.66
- Analyst Decision
- SERV Strong Buy
- EDIT Buy
- Analyst Count
- SERV 3
- EDIT 13
- Target Price
- SERV $14.67
- EDIT $9.38
- AVG Volume (30 Days)
- SERV 6.4M
- EDIT 2.3M
- Earning Date
- SERV 11-07-2024
- EDIT 11-04-2024
- Dividend Yield
- SERV N/A
- EDIT N/A
- EPS Growth
- SERV N/A
- EDIT N/A
- EPS
- SERV N/A
- EDIT N/A
- Revenue
- SERV $1,679,360.00
- EDIT $61,759,000.00
- Revenue This Year
- SERV $901.23
- EDIT N/A
- Revenue Next Year
- SERV $675.79
- EDIT N/A
- P/E Ratio
- SERV N/A
- EDIT N/A
- Revenue Growth
- SERV 692.32
- EDIT 150.95
- 52 Week Low
- SERV $1.77
- EDIT $2.59
- 52 Week High
- SERV $30.00
- EDIT $11.69
- Technical
- Relative Strength Index (RSI)
- SERV N/A
- EDIT 35.77
- Support Level
- SERV N/A
- EDIT $3.07
- Resistance Level
- SERV N/A
- EDIT $3.38
- Average True Range (ATR)
- SERV 0.00
- EDIT 0.23
- MACD
- SERV 0.00
- EDIT -0.03
- Stochastic Oscillator
- SERV 0.00
- EDIT 8.64
About SERV Serve Robotics Inc. Common Stock
Serve Robotics Inc is developing next-generation robots for last-mile delivery services. Its first product is a zero-emission robot that serves people in public areas, Starting with food delivery. It has developed an advanced, AI-robotics mobility platform, with last-mile delivery in cities as its first application.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.